Abstract. We investigated the effects of antidepressants on the gene expression profile and behavior of olfactory-bulbectomized (OBX) rats. Removal of the main olfactory bulbs in rats alters neuronal function in brain areas involved in emotional regulation, resulting in maladaptive behavioral patterns similar to the symptoms of patients with depression. Previously, we found that OBX-induced behavioral and neuronal abnormalities were completely rescued by chronic treatment with SNC80, an opioid delta agonist, as well as with classical monoaminergic antidepressants. Thus, to determine the basis for this effect, we analyzed gene expression in OBX rat frontal cortex using a GeneChip ® rat Genome oligonucleotide array after imipramine or SNC80 treatment. We found that imipramine and SNC80 induced the following systematic changes in OBX rats: zinc ion binding; hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides; protein serine / threonine kinase activity; N-acetyltransferase activity; protein modification process; regulation of cellular process; and regulation of neurotransmitter levels. Defining the roles of candidate neuronal systems in antidepressant-induced neural changes are likely to transform the course of research on the biological basis of mood disorders.
Introduction
Antidepressants are very effective agents for preventing and treating depression and have been used clinically for more than 50 years. Typical antidepressants significantly increase the synaptic concentration of norepinephrine and / or serotonin. However, a latency period of several weeks generally elapses before therapeutic effects of antidepressants are observed. This delayed action could be due to either the indirect regulation of other neuronal signal transduction systems or the regulation of gene transcription following chronic treatment. Indeed, antidepressants have been shown to affect the expression of immediate early genes and transcription factors, including c-fos, FosB, junB, NGF1-A, and CREB (1). These regulatory proteins activate or repress genes that encode specific proteins and may be involved in antidepressant-induced alterations of central nervous system (CNS) function.
Pharmacogenomics is a powerful tool that can be used to identify neuronal systems affected by antidepressants. GeneChip ® technology, which is one of the most useful tools of pharmacogenomics, can determine the expression of several tens of thousands of genes and can help us understand the state of the brain after chronic antidepressant treatments. GeneChip ® analysis has been used to study the effects of chronic antidepressant treatment in normal animals (2, 3) , and some candidate genes and hypotheses about antidepressant actions have been indicated. However, the effect of antidepressants on gene expression in animal depression models is not well understood. Hence, comprehensive gene expression analysis in a valid animal model of depression in which antidepressants are applied is much needed. The olfactory bulbectomized (OBX) rat is considered to be one of the important animal models of depression in terms of face and predictive validity. Olfactory bulbectomy results in a complex constellation of behavioral, neurochemical, neuroendocrine, and neuroimmune alterations, many of which reflect symptoms reported in patients with major depression (4) . These changes typically require 1 -2 weeks to develop, and they occur independent of sensory deprivation (4, 5) . Many investigators have demonstrated that the behavioral effects of olfactory bulbectomy include an abnormal, stress-induced increase in locomotor activity and increases in various measures of irritability and hyperemotionality (6 -11) . Such behaviors resemble psychomotor agitation, a diagnostic criterion for depression. In addition, olfactory bulbectomy has been reported to alter adrenergic, serotonergic, and excitatory amino acid receptors in cortical and limbic areas in a fashion similar to the receptor alterations observed in suicide victims, and immune functions are suppressed in a manner consistent with the immunosuppression seen in clinical depression (5, 7, 9, 12) . Other models of depression such as learned helplessness and chronic mild stress (13, 14) react to acute antidepressant treatment. By contrast, OBX rats are unique in their sensitivity to chronic but not acute administration of clinically efficacious antidepressants (15 -20) .
We have recently reported that the nonpeptidic deltaopioid agonist SNC80 displays naltrindole-sensitive antidepressant-like properties in OBX rats (21) . The delta-opioid receptor system is sometimes associated with symptoms of depression as well as with antidepressant effects. Delta-opioid receptor knockout mice exhibit depressive-like responses in the forced swim test and anxiogenic-like responses in the elevated plus-maze test (22) . In addition, activation of the delta-opioid receptor has antidepressant-like properties in many animal models. BUBU, a selective delta-opioid agonist, showed antidepressant-like effects in the learned helplessness model of depression (23) . Increasing levels of endogenous delta-opioid peptides with enkephalinase inhibitors such as RB101 result in antidepressant-like effects in the forced swim test and the learned helplessness model of depression (23, 24) .
In the present study, we used GeneChip ® technology to carry out the first ever comprehensive gene expression analysis of OBX rats treated with imipramine and SNC80, two drugs with different mechanisms of action. We sought to identify the functional class of genes affected by drug treatments and aimed to advance our hypothesis on the mechanism underlying antidepressant action. It is reasonable to assume that interactions exist among neuronal systems involved in the mechanism of antidepressant action; we tried to identify neuronal systems in OBX rats affected by imipramine and / or SNC80.
Materials and Methods

Drugs
The drugs used in the present study were imipramine (Sigma Chemical Co., St. Louis, MO, USA) and (+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC80) (Toray Industries, Inc., Tokyo). All drugs were dissolved in physiological saline. Rats were injected s.c. at a drug dose of 1.0 ml / kg body weight.
Animals
Sixteen male 8-week-old (200 -240 g) Wistar rats (Tokyo Laboratory Animals Science, Tokyo) were used. They had free access to food and water in an animal room that was maintained at 22 ± 1°C with a 12-h lightdark cycle (lights on automatically at 8:00 a.m.). This study was carried out in accordance with the Guide for the Care and Use of Laboratory Animals of Hoshi University, which is accredited by the Japanese Ministry of Education, Culture, Sport, Science, and Technology.
Olfactory bulbectomy-induced hyperemotionality in rats Animals were anesthetized with sodium pentobarbital (40 mg / kg, i.p.) and placed in a stereotactic apparatus (ASI Instruments, Inc., Warren, MI, USA). The olfactory bulbs were removed by suction. Postoperatively, animals were housed in single cages. At 14 days postsurgery, hyperemotionality was measured using a modified procedure (25, 26) . Rats' responses were scored to the following stimuli: i) The "attack response" was scored by presenting a rod 4 -5 cm in front of the rat's snout; ii) the "startle response" was scored by blowing air onto the rat's dorsum (air was delivered through a 5-ml syringe); iii) the "struggle response" was scored by handling the rat with a gloved hand; and iv) the "fight response" was scored by pinching the rat's tail with a mosquito forceps. A trained researcher performed these operations. The responses were graded as follows: 0, no response; 1, slight response; 2, moderate response; 3, marked response; and 4, extreme response. For each emotional response, vocalization during the test was also scored and graded as follows: 0, no vocalization; 1, occasional vocalization; and 2, marked vocalization. The vocal score was added to each emotional response score.
We measured the emotional response score of each animal within 5 min in one day. Only rats that exhibited hyperemotionality (score: >14) were selected for further study in the drug administration experiments. Imipramine (10 mg / kg) or SNC80 (10 mg / kg) was administered once daily for a total of 7 days. On the 8th day after the 14-day post-surgical period, emotional responses were measured 24 h after drug administration. The observers were kept unaware of the drug treatment. We determined the effective dose of imipramine and SNC80 according to our previous experiments (21, 27) Data are expressed as means ± S.E.M. Statistically significant differences between groups were assessed with one-way analysis of variance (ANOVA) followed by the Tukey-Kramer test. Analyses were made using StatView statistical software SAS system Ver. 6.12 (SAS Institute, Inc., Cary, NC, USA).
Sample preparation for GeneChip
®
After the emotional response measurements, total RNA was extracted from rat frontal cortex using the Isogen reagent (Nippon Gene Co., Tokyo). Micorarray analysis was performed according to the manufacturer's protocol (Affymetrix, Santa Clara, CA, USA). Briefly, 5 µg of total RNA was used for cDNA synthesis by oligo-dT and SuperScript II reverse transcriptase, followed by in vitro transcription and biotin labeling. Biotinylated cRNA was fragmented, and 15 µg of the fragmented cRNA was hybridized to a GeneChip ® Rat Genome 230 2.0 array (Affymetrix), which contains probes for about 30,000 genes. The quality of total RNA and cRNA was analyzed on a BioAnalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA). Each sample from an individual rat was hybridized to an array. The samples were hybridized at 45°C for 16 h under constant rotation (60 rpm) using a GeneChip ® Hybridization Oven 640 (Affymetrix). After hybridization, microarrays were washed, stained with streptavidin phycoerythrin in a GeneChip ® Fluidics Station 450 (Affymetrix), and scanned in a GeneChip ® Scanner 3000 (Affymetrix).
Quality control criteria
Tissue preparations and RNA extractions were performed on a single batch by the same investigator in order to minimize experimental variability. All samples yielded equal amounts of biotinylated RNA. An average of 91.8 ± 13.3 µg (mean ± S.D.) of biotinylated RNA was obtained from the frontal cortex for in vitro transcription. All quality control criteria defined by Affymetrix were met by the samples, and no differences between the experimental groups were observed. The average percent "present" call across all arrays was 66.0 ± 2.4%, and 3'/ 5' glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 1.3 ± 0.1 (averages ± S.D.). Background and noise were 65.6 ± 11.1 and 3.8 ± 1.3, respectively (average ± S.D.).
Data analyses
The raw microarray data were processed with Affymetrix MicroArray Suite software, version 5.0 (28) . To normalize the probe intensity across different chips, the top 2% and bottom 2% of signal intensities were excluded, and then the means were calculated. The data were then imported into GeneSpring 7.2 software (Silicon-Genetics, Redwood, CA, USA). Genes that were "present" calls across all arrays were used in the hierarchical clustering analysis. Finally, 16,342 genes were analyzed. Each sample was categorized according to gene expression pattern. The functional clustering analysis and the gene expression pattern analysis used genes that were filtered by two processes: i) all "present" called genes in OBX group; ii) the difference in OBX group was within 0.5 SD. A total of 18,509 genes passed these filtering procedures. Differentially expressed genes compared with the OBX group were defined according to the following criteria: i) 1.2-fold change in each imipramine and SNC80 treatments group; ii) P<0.05 in the two-tailed Student's t-test in each imipramine and SNC80 treatments group. The common genes of passed criteria between imipramine and SNC80 treatments group were analyzed. For the functional clustering analysis, the resulting 577 genes were analyzed using The Database for Annotation, Visualization, and Integrated Discovery (DAVID 2.0) (released 6/ 2007) based on Gene Ontology (GO) annotations. DAVID is a web-based application that allows users to access relational databases for functional annotations (http://david.abcc.ncifcrf.gov / home.jsp) (29) . The Fisher's exact test was applied to evaluate the statistical significance of the association between the 577 genes and GO database (P<0.01). GO terms were described according to the GO database (http://www.geneontology. org / ).
Results
Emotional and behavioral changes after imipramine or SNC80 treatment
In the present study, we determined emotional and behavioral changes after imipramine or SNC80 treatment in OBX rats (Fig. 1) . The total emotional response scores of OBX rats were significantly higher than those of sham-operated rats 14 days post-surgery. The emotional responses of OBX rats were not significantly affected by vehicle after chronic administration for 7 days (Fig. 1a) . Chronic administration of imipramine or SNC80 at a dose of 10 mg/ kg (i.p.), however, significantly reduced hyperemotionality in OBX rats (Fig. 1a) . The attack, startle, struggle, and fight response scores of OBX rats are shown in Fig. 1b . Vehicle-treated OBX rats clearly had significantly higher attack, startle, struggle, and fight responses than sham rats. Chronic imipramine administration (10 mg / kg, i.p.) significantly reduced the attack, fight, and struggle response scores of vehicle-treated OBX rats (Fig. 1b) . Chronic SNC80 administration (10 mg / kg, i.p.) completely abolished all hyperemotionality responses in OBX rats (Fig. 1b) .
Gene expression pattern after imipramine or SNC80 treatment
To address whether variations in gene expression levels can explain the effects of imipramine and SNC80 on emotional response, we performed unsupervised hierarchical clustering analysis. Samples assigned to the same cluster had similar gene expression levels, whereas samples assigned to different clusters had dissimilar gene expression levels. In this analysis, samples of the same group were assigned as a single cluster (Fig. 2) . To confirm the expression patterns, we assigned the 577 genes that showed significant differential expression to five classes (Fig. 3) . Drug treatment was correlated with expression levels of 35 genes returning back to that of sham levels (Fig. 3c) . Interestingly, we identified only 3 genes that responded oppositely to imipramine and SNC80 treatment (Fig. 3e) .
Functional clustering after imipramine or SNC80 treatment
To determine whether the 577 genes affected by imipramine and SNC80 treatment correspond to specific functional classifications, we used supervised queries of the GO database. GO classifies genes into three main categories according to i) biological process, ii) molecular function, and iii) cellular component. Biological / functional classifications are then organized according to GO pathways, which are linked as hierarchical clusters, with the most general function positioned at a primary node and more specific functions positioned at subsequent nodes. Table 1 lists the functional classifica- Fig. 3 . Classification of imipramine-and SNC80-responding genes based on gene expression patterns. A total of 577 genes displayed significant differential expression following treatment with imipramine and SNC80. These genes were assigned to five classes based on their response to drug treatment: a: increased expression levels, b: decreased expression levels, c: expression levels returned to those of sham, d: expression levels opposite to those of sham, e: expression response to imipramine treatment opposite to that to SNC80 treatment. Up or down thresholds are set to an observed difference of 1.2-fold. The number of differentially expressed genes is listed in parentheses. Gene ontology terms are organized hierarchically, with categories of a more general nature being situated at primary, top-level branches and categories of a more specific nature situated at secondary, lower-level branches. tion of the genes affected by imipramine and SNC80 treatment. Table 2 lists differentially expressed genes identified according to selected enriched gene ontology terms. Figure 4 showed the systematic scheme of Table 1 .
Discussion
In the present study, chronic administration of imipramine or SNC80 significantly reduced hyperemotionality in OBX rats (Fig. 1) . The changes of emotional response were consistent with our previous report (21) .
On the other hand, we have previously performed several behavioral experiments including the elevated plus maze test in OBX rats (21, 30) . OBX rats showed a decrease of the time spent and the number of entries in the open arm of a plus-maze test with vehicle treatment for 7 days, and a recovery of those with treatment of SNC80 and desipramine (21) . Thus, the molecular systems affected by imipramine and SNC80 treatment in OBX rats may also be related to antianxiety-like action in addition to antidepressant-like action.
In the frontal cortex, glucose metabolism, blood flow, and electroencephalograph activity are altered in depressed patients (31) . Thus, we analyzed frontal cortex samples in this study. However, it is necessary to examine the gene expression profile in the hippocampus and other related brain structures in future.
Gene expression analysis can be used to explain the effects of drugs. Hierarchical cluster analysis can reveal drug action characteristics and thus can be used to estimate the differences and similarities in the actions of various drugs. In the present study, we used gene expression analysis to determine the mechanisms of action of two drugs, imipramine and SNC80, in an animal model of depression. Hierarchical clustering analysis of gene expression data assigned samples from the same drug treatment group into a single cluster (Fig. 2) , indicating these samples shared similar gene expression patterns. Indeed, we found that gene expression patterns were similar in OBX rats treated chronically with the antidepressant imipramine and those
Runx1t1
Runt-related transcription factor 1; translocated to, 1 (cyclin D-related) BF408914 treated chronically with the delta-opioid agonist SNC80. This is consistent with findings from primary cultures treated in vitro with CNS acting drugs (opioids, antidepressants, and antipsychotic drugs) (32) . Microarray analysis of these cells showed that the gene expression profile of cells treated with antidepressants was similar to that of cells treated with a delta-opioid agonist.
The similarity in the effects of imipramine and SNC80 on gene expression was also seen when significant changes in gene expression were analyzed further (Fig. 3) . A total of 577 genes were significantly affected by imipramine and SNC80 treatment. Of the 577 genes, Fig. 4 . Functional clustering of the genes affected by imipramine and SNC80 treatment. Biological /functional classifications are organized according to GO pathways, which are linked as hierarchical clusters, with the most general function positioned at a primary node and more specific functions positioned at subsequent nodes. The red characters indicate the functional classifications, which showed statistical significance of association between the 577 genes and GO database (P<0.01). Differentially expressed genes identified according to selected enriched gene ontology terms (highlighted in blue) are shown in Table 2 .
only 3 genes responded oppositely to imipramine and SNC80 treatment (Fig. 3e) , suggesting that the CNS functions affected by these drugs were more similar than dissimilar. Interestingly, 35 genes responded to drug treatment by adjusting their expression levels to that of the sham (Fig. 3c) . Taken together, our findings indicate that in OBX rats the mechanisms underlying drug action differ from those mediating emotional changes. In the clinical situation, the pathogenic development of depression may be different from the mechanism of antidepressant action.
The elucidation of the mechanisms that direct antidepressant actions should be approached from the viewpoint of the CNS as a whole. One such approach is based on the analysis of a large number of gene expression changes. To date, antidepressants have been reported to affect the expression of many immediate early genes and transcription factors. These regulatory proteins induce many changes in the expression of downstream genes. GeneChip ® technology has proven to be very useful for analyzing a large number of genes. However, replicating gene expression data has been problematic. The reproducibility of microarray techniques has been evaluated by way of laboratory correlations and different platform correlations (cDNA microarrays and oligonucleotide chips). These studies showed that gene-by-gene comparisons show exceedingly poor correlation among platforms and across laboratories (33 -38) . However, the reproducibility improved substantially when microarray analysis was based on commonly accepted biological GO terms as opposed to analysis based on gene-by-gene comparisons (35) . Consequently, we analyzed mechanisms underlying antidepressant actions based on functional classes rather than on individual gene comparisons. Identifying the functional classes that are affected by antidepressants would lead to the identification of candidate neuronal systems affected by antidepressant treatments. It will be necessary to analyze the individual gene expression changes in future studies.
On the basis of the above analysis schema, we identified common functional changes induced by imipramine and SNC 80 in OBX rats. Using the GO database, we also related the changes we observed in gene expression to specific functions, which included zinc ion binding; hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides; protein serine / threonine kinase activity; N-acetyltransferase activity; protein modification process; regulation of cellular process; and regulation of neurotransmitter levels.
We examined the gene expression analysis at 24 h after the last drug administration to exclude possible acute effects by the drug treatments. However, it is difficult to distinguish antidepressant-like effects from withdrawal effects. In the future, it will be necessary to make clear which functional classes are important for recovery of depressed patients.
Zinc ion binding
During the last several years, important roles of zinc in the psychopathology and therapy of depression have been identified. Recently, clinical data have revealed lower serum zinc concentration in depressed patients (39, 40) . Clinical studies have shown zinc supplementation to be beneficial in the antidepressant therapy of depressed patients (41) . Zinc also exhibits antidepressantlike effects in behavioral tests and models used to evaluate antidepressant activity, such as the forced swim test and tail suspension test (42 -44) , and in olfactory bulbectomy, chronic mild stress (CMS), and chronic unpredictable stress (CUS) animal models of depression (45 -47) . A recent study demonstrated that acute and chronic treatment with zinc has antidepressant-like effects in OBX rats tested in a passive avoidance task (45) . Zinc also significantly decreased the time of walking and number of rearing and peeping in the OBX rats (45) . Moreover, chronic zinc treatment reversed the CMS-induced reduction in the consumption of 1% sucrose solution by rats (46) . Recently, prolonged zinc treatment has been shown to prevent a deficit in fighting behavior in rats in the CUS model (47) . Moreover, in the same model, zinc supplementation potentiated the antidepressant effects of imipramine (47) . All of these animal data strongly suggest that zinc possesses possible antidepressant activity.
Hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides Genes encoding proteins that participate in the hydrolysis of phosphorus-containing acid anhydrides are thought to be involved in various brain functions. Therefore, it is difficult to ascertain the specific action of antidepressants based on this category. However, many genes assigned to this category are related to the ATPbinding cassette (ABC) transporter, which regulates the concentration of drugs in the CNS. Antidepressants are reportedly effluxed from the CNS by the ABC transporter (48, 49) . In addition, various antidepressant compounds are differentially recognized as substrates for the ABC transporter (48, 49) , and certain substrates such as St. John's wort, a known herbal antidepressant, increase the expression and function of the ABC transporter (50, 51) . Indeed, antidepressants may affect ABC transporter activity, thus regulating permeability of the blood brain barrier itself.
Protein serine/ threonine kinase activity, protein modification process, and regulation of cellular process
Because genes encoding proteins involved in protein serine / threonine kinase activity, protein modification, or regulation of cellular process have diverse functions, it is difficult to identify the specific actions of antidepressants on the basis of these categories. Each category contained many axonal/dendritic-related genes, N-glycan biosynthesis-related genes, and signal transductionrelated genes. However, the present study did not determine the specific function of the genes in the CNS. Further studies are needed.
N-Acetyltransferase activity
A gene that is related to N-acetyltransferase activity has been reported to be involved in antidepressant actions. Serotonin N-acetyltransferase catalyzes the ratelimiting step in the biosynthesis of the circadian hormone melatonin from serotonin. Chronic but not acute fluoxetine administration increases the expression of serotonin N-acetyltransferase in the prefrontal cortex and the hippocampus (52, 53) .
This category also contained the Camello protein family and O-GlcNAc transferase protein. Camello proteins, which are localized in the Golgi complex, inhibit gastrulation in Xenopus laevis. Camello proteins participate in the acetylation of sugar residues in glycoproteins (54) . O-GlcNAc transferase catalyzes the addition of a single N-acetylglucosamine to proteins. Therefore, antidepressants may affect N-acetyltransferase-regulated biosynthesis, especially the modification of glycoproteins.
Regulation of neurotransmitter levels
Antidepressants may regulate neurotransmitter levels, especially glutamate levels, in the synaptic cleft via regulation of exocytosis machinery and uptake machinery. Some clinical studies suggest that the glutamatergic system in depressed patients is pathological. For example, plasma and cerebrospinal fluid glutamate levels and glutamate / glutamine ratios are altered in depressed patients (55 -57) . More recent proton magnetic resonance spectroscopic analyses have identified alterations in glutamate levels in the anterior cingulate cortex and occipital cortex of depressed patients (58, 59) . In addition, decreases in glial cell densities observed in depressed patients (60 -62) may result in decreased glial glutamate transporter expression, thereby reducing the capacity to regulate synaptic concentrations of glutamate. Indeed, one microarray study suggested that glial glutamate transporter expression is decreased in the anterior cingulate cortex and dorsolateral prefrontal cortex of depressed patients (63) .
Glutamate uptake by glia is the primary mechanism for clearing glutamate from the synaptic cleft. Therefore, a glial deficit may contribute to glutamate hyperactivity in depressed patients.
The inhibition of glutamate release by antidepressant treatment has been reported. Two different drugs (imipramine and phenelzine) were found to reduce depolarization-evoked glutamate overflow from slices of prefrontal cortex after both acute and chronic treatment (64) . Acute exposure to fluoxetine reduces depolarization-evoked glutamate release from cerebrocortical synaptosomes in vitro via inhibition of P / Q-type Ca 2+ channels (65) . Chronic antidepressant treatment suppresses depolarization-evoked release of glutamate from hippocampal synaptosomes, by reducing syntaxin-1/ CaM kinase II interaction, activity that promotes neurotransmitter release. This treatment also increases syntaxin-1 / Munc-18 interaction, an activity that reduces neurotransmitter release (66) .
In the present study, we identified an astrocyteexpressed gene that regulates glutamate levels (Glul, Slc1a3). Previously, we also found an astrocyteexpressed gene, Ndrg2, whose expression was decreased by antidepressant treatments in the frontal cortex (67) . These results suggest that antidepressants affect not only genes expressed by neurons but also by genes expressed by astrocytes. One of the antidepressant actions may regulate glutamate homeostasis via astrocytes.
Conclusions
In the present study, comprehensive gene expression analyses showed that two drugs with different mechanisms of action affected common neuronal systems in the frontal cortex of OBX rats. Defining the roles of these candidate neuronal systems in antidepressantinduced neural changes is likely to transform the course of research on the biological basis of mood disorders. Such detailed knowledge will have profound effects on the diagnosis, prevention, and treatment of depression.
